Skip to content
Study details
Enrolling now

Safety & Effectiveness of Autologous Regenerative Cell Therapy on Pain & Inflammation of Osteoarthritis of the Hip

VivaTech International, Inc.
NCT IDNCT02844764ClinicalTrials.gov data as of Apr 2026
Phase

Phase 2

Target enrollment

4,000

Study length

about 11 years

Ages

18–90

Locations

1 site in PA

Why this study is shown

Matches osteoarthritisActively enrollingPHASE2

What this study is about

Researchers are testing a treatment called StroMed plus platelet rich plasma (PRP) for pain and inflammation in people with hip osteoarthritis. The trial will follow 50 patients initially, with plans to expand to include 4,000 more participants over 4049 days.

Simplified from trial records by PatientMatch.

What you may be asked to do

  • 1.Receive [StroMed + platelet rich plasma (PRP)]

Participation Burden

What's physically and logistically required of participants.

Logistics & Travel
In-person visits

Requires travel to a study site

Physical Intervention
Standard

How treatment is administered

Treatment Assignment
All receive treatment

Everyone gets the investigational treatment.

Extracted study details

Pulled from the trial record to show what is being tested and what the study is measuring.

Endpoints

Secondary: Change is being assessed by MRI of afflicted joint, Change is being assessed for the NRS survey (Numerical Rating Scale for Pain), Change is being assessed for the SF36 survey (Short Form Quality of Life Survey)

Body systems

Musculoskeletal